Loading...
Loading...
LEXX| Name | Value |
|---|---|
| Revenues | 151.3K |
| Cost of Revenue | 4.8K |
| Gross Profit | 146.5K |
| Operating Expense | 1,285.6K |
| Operating I/L | -1,139.1K |
| Other Income/Expense | -45.9K |
| Interest Income | 7.3K |
| Pretax | -1,185.0K |
| Income Tax Expense | 40.2K |
| Net Income/Loss | -1,179.3K |
Lexaria Bioscience Corp. is a biotechnology company specializing in drug delivery technology. Its patented DehydraTECH enhances the oral delivery of active pharmaceutical ingredients, significantly increasing bio-absorption and reducing onset time. The technology is applicable to cannabinoids, nicotine, anti-viral drugs, NSAIDs, PDE5 inhibitors, and more. With 23 patents granted and approximately 50 patents pending globally, the company operates a licensed in-house research laboratory. By licensing its technology and intellectual property, Lexaria Bioscience generates revenue from pharmaceutical and biotech companies seeking to improve the effectiveness of their drug delivery methods.
